A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat i starsze.
- •Potwierdzona białaczka limfocytowa/chłoniak małych limfocytów, który wrócił lub nie zareagował na poprzednie leczenie.
- •Wcześniej stosowano leczenie inhibitorami BTK (zarówno stałymi, jak i niestabilnymi) oraz inhibitorem BCL-2.
- •Zgoda na udział w badaniu i zrozumienie jego celu.
✗ Disqualifies
- •Stwierdzona lub podejrzewana ostra białaczka prolimfocytowa lub transformacja Ritchtera.
- •Stosowanie innych badanych leków lub terapii przeciwnowotworowych w ciągu ostatnich 14 dni lub 5 okresów połowicznego rozpadu (w zależności od tego, co krótsze).
- •Przyjmowanie steroidów w dawce powyżej 20 mg prednizolonu dziennie w ciągu 7 dni przed rozpoczęciem leczenia w badaniu (chyba że jako przygotowanie do badania obrazowego).
- •Wcześniejsze leczenie degraderami BTK, terapią komórkami CAR-T lub przeszczepem komórek macierzystych w ciągu ostatnich 90 dni.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (32)
City of Hope
Duarte, United States
Colorado Blood Institute
Denver, United States
University of Miami
Coral Gables, United States
Florida Cancer Specialists
Sarasota, United States
Fort Wayne Oncology and Hematology
Fort Wayne, United States
Hematology Oncology of Indiana
Indianapolis, United States
University of Iowa
Iowa City, United States
Maryland Oncology Hematology
Silver Spring, United States
Karmanos Cancer Center
Detroit, United States
Duke University
Durham, United States
Novant Health Cancer Institute
Winston-Salem, United States
University of Cincinnati
Cincinnati, United States
Oncology Hematology Care
Fairfield, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
SCRI Oncology Partners
Nashville, United States
Texas Oncology - Center South
Austin, United States
University of Utah
Salt Lake City, United States
Virginia Cancer Specialists, PC
Fairfax, United States
Oncology & Hematology Associates of Southwest VA
Norfolk, United States
Virginia Oncology Associates
Norfolk, United States
CHU de Nantes
Nantes, France
Azienda Ospedaliero-Universitaria di Alessandria SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Bologna, Italy
Ospedale San Raffaele S.r.l.
Milan, Italy
AUSL della Romagna UO Ematologia
Ravenna, Italy
Pratia Hematologia Sp. z o.o.
Katowice, Poland
Pratia S.A.
Krakow, Poland
Aidport Sp. z o.o.
Skorzewo, Poland
Pratia Warszawa / Pratia MTZ
Warsaw, Poland
Oxford University Hospitals NHS Foundation Trust
Headington, United Kingdom
The Royal Marsden NHS Foundation Trust
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Trial contact
Additional Site Contact Information
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.